Next Article in Journal
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
Previous Article in Journal
Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre
 
 
Article

Article Versions Notes

Curr. Oncol. 2024, 31(3), 1529-1542; https://doi.org/10.3390/curroncol31030116
Action Date Notes Link
article xml file uploaded 15 March 2024 08:15 CET Original file -
article xml uploaded. 15 March 2024 08:15 CET Update https://www.mdpi.com/1718-7729/31/3/116/xml
article pdf uploaded. 15 March 2024 08:15 CET Version of Record https://www.mdpi.com/1718-7729/31/3/116/pdf
article html file updated 15 March 2024 08:16 CET Original file https://www.mdpi.com/1718-7729/31/3/116/html
Back to TopTop